Accord-UK launches Pelgraz injector and app
The product is designed to help reduce hospital trips for cancer patients
Read More
Tag: pegfilgrastim
Napp launches pegfilgrastim biosimilar in the UK
Napp Pharmaceuticals has launched Pelmeg – a pegfilgrastim biosimilar – across the UK.
Read More
Mundipharma launches Pelmeg biosimilar in Europe
Mundipharma has announced the launch of Pelmeg (pegfilgrastim), a biosimilar of Neulasta, following its European Commission (EC) approval in November 2018.
Read More
EU OKs Mundipharma’s Neulasta biosimilar
The Mundipharma network of independent associated companies says European regulators have approved use of Pelmeg, a biosimilar of Amgen’s white blood cell booster Neulasta.
Read More
US OKs first biosimilar of Amgen’s Neulasta
Mylan and Biocon’s Fulphila has become the first biosimilar of Amgen’s Neulasta to be approved by the US Food and Drug Administration.
Read More
Gedeon’s re-filed Neulasta biosimilar under EU review
European regulators have accepted a resubmission of Gedeon Richter’s biosimilar to Amgen’s Neulasta.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
